SOTORASIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H30F2N6O3
Molecular Weight	560.5944
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0
Stereo Comments	AXIAL, R

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=C(N2C(=O)N=C(N3CCN(C[C@@H]3C)C(=O)C=C)C4=CC(F)=C(N=C24)C5=C(O)C=CC=C5F)C(C)=CC=N1

InChI

InChIKey=NXQKSXLFSAEQCZ-SFHVURJKSA-N

InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C30H30F2N6O3
Molecular Weight	560.5944
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://pubmed.ncbi.nlm.nih.gov/34357500|https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf

Sotorasib (LUMAKRAS™) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. Sotorasib is an inhibitor of KRASG12C, a tumor-restricted, mutant-oncogenic form of the RAS GTPase, KRAS. Sotorasib forms an irreversible, covalent bond with the unique cysteine of KRASG12C, locking the protein in an inactive state that prevents downstream signaling without affecting wild-type KRAS. Sotorasib blocked KRAS signaling, inhibited cell growth, and promoted apoptosis only in KRAS G12C tumor cell lines. Sotorasib inhibited KRASG12C in vitro and in vivo with minimal detectable off-target activity. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GTPase KRas 5 Target ID: CHEMBL2189121 Sources: https://pubmed.ncbi.nlm.nih.gov/31820981\|https://pubmed.ncbi.nlm.nih.gov/32910655\|https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf	Inhibitor 8504		30.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf	Primary		Approved 8583	LUMAKRAS Approved Use LUMAKRAS is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. Launch Date 2021

C_max

Value	Dose	Analyte	Population
6.44 μg/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 \| https://pubmed.ncbi.nlm.nih.gov/34903582/	180 mg 1 times / day steady-state, oral dose: 180 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
6.31 μg/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 \| https://pubmed.ncbi.nlm.nih.gov/34903582/	360 mg 1 times / day steady-state, oral dose: 360 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.45 μg/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 \| https://pubmed.ncbi.nlm.nih.gov/34903582/	720 mg 1 times / day steady-state, oral dose: 720 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.39 μg/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94	960 mg 1 times / day steady-state, oral dose: 960 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
6690 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	960 mg single, oral dose: 960 mg route of administration: Oral experiment type: SINGLE co-administered:	SOTORASIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
7880 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	960 mg single, oral dose: 960 mg route of administration: Oral experiment type: SINGLE co-administered:	SOTORASIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
8320 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	960 mg 1 times / day multiple, oral dose: 960 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7180 ng/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	960 mg 1 times / day multiple, oral dose: 960 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
31.7 μg × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 \| https://pubmed.ncbi.nlm.nih.gov/34903582/	180 mg 1 times / day steady-state, oral dose: 180 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
38.9 μg × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 \| https://pubmed.ncbi.nlm.nih.gov/34903582/	360 mg 1 times / day steady-state, oral dose: 360 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
42.1 μg × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 \| https://pubmed.ncbi.nlm.nih.gov/34903582/	720 mg 1 times / day steady-state, oral dose: 720 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
32.4 μg × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94	960 mg 1 times / day steady-state, oral dose: 960 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
28700 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	960 mg single, oral dose: 960 mg route of administration: Oral experiment type: SINGLE co-administered:	SOTORASIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
31500 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	960 mg single, oral dose: 960 mg route of administration: Oral experiment type: SINGLE co-administered:	SOTORASIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
81500 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	960 mg 1 times / day multiple, oral dose: 960 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
43900 ng × h/mL OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=255	960 mg 1 times / day multiple, oral dose: 960 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.13 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 \| https://pubmed.ncbi.nlm.nih.gov/34903582/	180 mg 1 times / day steady-state, oral dose: 180 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
5.53 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 \| https://pubmed.ncbi.nlm.nih.gov/34903582/	360 mg 1 times / day steady-state, oral dose: 360 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.75 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94 \| https://pubmed.ncbi.nlm.nih.gov/34903582/	720 mg 1 times / day steady-state, oral dose: 720 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5.07 h OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=94	960 mg 1 times / day steady-state, oral dose: 960 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SOTORASIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
11.2% OTHER GOV'T https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=58 \| https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf#page=89			SOTORASIB plasma	Homo sapiens

Doses

Dose	Population	Adverse events
960 mg 1 times / day steady, oral Highest studied dose Dose: 960 mg, 1 times / day Route: oral Route: steady Dose: 960 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf	Disc. AE: Vomiting, Gastric ulcer... Other AEs: Pneumonia... AEs leading to discontinuation/dose reduction: Vomiting (1 patient) Gastric ulcer (1 patient) Pneumonitis (2 patients) Hepatobiliary disorders (3 patients) Haemorrhage intracranial (1 patient) Cardiac arrest (1 patient) Alanine aminotransferase increased (4 patients) Aspartate aminotransferase increased (4 patients) Pneumothorax (2 patients) Liver function test increased (1 patient) Dehydration (1 patient) Neoplasms (1 patient) Dyspnea (1 patient) Pneumothorax (1 patient) Gastric ulcer (2 patients) Other AEs: Pneumonia (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 substrate 1946	inducer 440 inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BCRP 910 MATE2-K 77 MATE1 415 P-gp 1741 CYP1A2 2153 CYP2C8 1057 CYP2B6 926 CYP2C19 2057	BCRP 697 Glutathione transferases 1 OATP1B3 435 MATE1 182 P-gp 2052 OATP1B1 503 MATE2K 6	CYP2B6 669 CYP2C8 198

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf Page: 10.0	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf Page: 10.0	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf Page: 10.0	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf Page: 10.0	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf Page: 10.0	no
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57.0	yes [IC50 0.44 uM]	no (co-administration study) Comment: No significant effect on metformin AUCinf and Cmax (0.985-fold and 0.996-fold) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57.0
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57.0	yes [IC50 120 uM]
MATE2-K 77	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57.0	yes [IC50 2.39 uM]	no (co-administration study) Comment: No significant effect on metformin AUCinf and Cmax (0.985-fold and 0.996-fold) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57.0
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57 \| 91	yes [IC50 60.2 uM]	yes (co-administration study) Comment: Increased digoxin AUCinf and Cmax by 1.214-fold and 1.914-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57 \| 91
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 252 \| 253	yes [Ki 18.1 uM]
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 252.0	yes
CYP2C8 1117	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 252.0	yes
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 252.0	yes
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91.0	yes	yes (co-administration study) Comment: Decreased midazolam AUCinf and Cmax by 0.47-fold and 0.52-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91.0

Drug as victim

Target	Modality	Activity	Clinical evidence
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91 \| 97		weak (co-administration study) Comment: Rifampicin decreased AUCinf and Cmax by 0.766-fold and 0.840-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91 \| 97
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91 \| 97		weak (co-administration study) Comment: Rifampicin decreased AUCinf and Cmax by 0.766-fold and 0.840-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91 \| 97
Glutathione transferases 1	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57.0	minor
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57 \| 91	minor	yes (co-administration study) Comment: Rifampicin decreased AUCinf and Cmax by 0.487-fold and 0.647-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57 \| 91
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57.0	no
MATE1 182	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91.0	no	no (co-administration study) Comment: No significant effect on sotorasib AUCinf and Cmax (0.910-fold and 0.812-fold) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91.0
MATE2K 6	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91.0	no	no (co-administration study) Comment: No significant effect on sotorasib AUCinf and Cmax (0.910-fold and 0.812-fold) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 91.0
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57.0	yes	weak (co-administration study) Comment: Itraconazole increased AUCinf by 1.261-fold but did not affect on Cmax (1.040-fold) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 57.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf Page: 42 \| 55

PubMed

Title	Date	PubMed
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.	2022-01	34919824
Sotorasib: First Approval.	2021-09	34357500
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.	2021-06-24	34096690
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.	2020-09-24	32955176

Patents

Sample Use Guides

In Vivo Use Guide

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf

Route of Administration: Oral

In Vitro Use Guide

Sotorasib inhibited the SOS1- catalyzed nucleotide exchange of KRASG12C (IC50 = 92.6 nM or ~51.9 ng/mL) but not wild-type (WT) KRAS (IC50 >250 uM).

Substance Class	Chemical Created by `admin` on `Wed Apr 02 00:10:03 GMT 2025` Edited by `admin` on `Wed Apr 02 00:10:03 GMT 2025`
Record UNII	2B2VM6UC8G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SOTORASIB

Official Name

English

6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-(1M)-1-(4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL)-4-((2S)-2-METHYL-4-(PROP-2-ENOYL)PIPERAZIN-1-YL)PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE

Preferred Name

English

SOTORASIB [JAN]

Common Name

English

SOTORASIB [ORANGE BOOK]

Common Name

English

sotorasib [INN]

Common Name

English

KRAS MUTANT-TARGETING AMG 510

Common Name

English

Sotorasib [WHO-DD]

Common Name

English

PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE, 6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-1-(4-METHYL-2-(1-METHYLETHYL)-3-PYRIDINYL)-4-((2S)-2-METHYL-4-(1-OXO-2-PROPEN-1-YL)-1-PIPERAZINYL)-

Systematic Name

English

PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE, 6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-1-(4-METHYL-2-(1-METHYLETHYL)-3-PYRIDINYL)-4-((2S)-2-METHYL-4-(1-OXO-2-PROPEN-1-YL)-1-PIPERAZINYL)-, (1R)-

Systematic Name

English

AMG-510

Code

English

LUMAKRAS

Brand Name

English

AMG510

Code

English

(1RA)-6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-4-((2S)-2-METHYL-4-(1-OXOPROP-2-EN-1-YL)PIPERAZIN-1-YL)-1-(4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL)PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE

Systematic Name

English

(1M)-6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-1-(4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL)-4-((2S)-2-METHYL-4-(PROP-2-ENOYL)PIPERAZIN-1-YL)PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE

Systematic Name

English

SOTORASIB [USAN]

Common Name

English

KRAS G12C INHIBITOR 9

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

654918